Reported 2 days ago
BMO Capital Markets has raised its price target for Merus N.V. (MRUS) from $96 to $110 while maintaining an Outperform rating, following positive Phase 2 data for its drug candidates petosemtamab and pembrolizumab intended for treating recurrent or metastatic HNSCC. The study showed a 63% Objective Response Rate and a 79% survival rate at 12 months, significantly outperforming pembrolizumab's standard care rates. Increased investor confidence is reflected in the approval probability rising from 85% to 90% due to favorable safety data.
Source: YAHOO